14 results about "Botulinum neurotoxin" patented technology

The present invention relates to aqueous saline solutions comprising dantrolene and optionally at least one additional active ingredient, such as botulinum neurotoxin, and their use for various therapeutic and / or aesthetic purposes. The solutions can be administered in any suitable manner, but have the advantage of being particularly well-suited for intramuscular injection.

The present invention relates to a method for preparing a composition comprising (A) a cross-linked material comprising one or more polysaccharide moieties covalently cross-linked with each other through ester bonds using one or more triazine-based activating agents, and (B) at least one botulinum toxin. Furthermore, the present invention relates to the composition obtainable by said method, and therapeutic and aesthetic uses of such composition.

Products, pharmaceutical compositions, methods of use, and kits are provided for treating a patient suffering from botulinum neurotoxin intoxication. Featured are single-domain variable heavy-chain (VHH) polypeptides (antibodies) that target and neutralize the light chain (LC) protease domains of botulinum neurotoxin (BoNT), i.e., BoNT LC / A and BoNT LC / B, and that advantageously provide late and post-exposure therapy for botulism patients. The LC / A toxin-binding and LC / B toxin-binding VHH polypeptides, which can be recombinantly produced, specifically bind to the LCs of the botulinum neurotoxins to inhibit toxin activity and treat intoxication.

Disclosed herein are methods of treatment of moderate to severe and very severe glabellar lines and lateral canthal lines using liquid botulinum neurotoxin compositions. Also disclosed are liquid compositions of botulinum neurotoxin.

Provided are a composition for stabilizing botulinum neurotoxin, a botulinum neurotoxin formulation including the same, and a polypeptide for use therein.

Methods for the isolation and purification of a botulinum neurotoxin protein (BONT) or a polypeptide comprising a BONT receptor-binding domain from a solution are disclosed here. The method comprises contacting the solution containing the protein or polypeptide with a matrix bound to it by a non-toxic non-hemagglutinin (NTNHA) under appropriate conditions for binding, washing the matrix to remove unbound materials, and eluting the protein or polypeptide with a solution that dissociates the bound protein from the NTNHA. Appropriate conditions for binding are a pH less than 7.5 (e.g., 6). Appropriate conditions for dissociation are a pH greater than or equal to 7.5 (e.g., 8). Specific compositions for the methods are also described.

A botulinum neurotoxin serotype E (BoNT / E) for use in treating a disorder or a cosmetic condition, wherein the BoNT / E provides a maximum inhibition of neurotransmitter secretion from a target cell or tissue 13 days or less after administration to a human subject and the inhibition is reduced but is greater than 25% at day 14 following administration. A method for treating a disorder or a cosmetic condition, the method comprising administering the aforementioned BoNT / E.

Disclosed herein is a botulinum neurotoxin (BoNT) polypeptide with a modified receptor binding domain (HC) having one or more amino acid mutations that modify the binding of the BoNT to the receptor. Specific mutations and combinations of mutations are also disclosed. Isolated modified HC, polypeptides comprising the modified HC, chimeric molecules, pharmaceutical compositions, and methods of making and using the same are also disclosed. Methods of identifying additional such modified receptor binding domains, are further disclosed.

The present invention relates to aqueous saline solutions comprising dantrolene and optionally also at least one additional active principle, such as botulinum neurotoxin, and their use for various therapeutic and / or aesthetic purposes. The solutions can be administered in any suitable way, but are advantageous in that they are particularly well adapted to intramuscular injection.

The present invention relates to the use of modified BoNT / A for the treatment of cervical dyskinesia, including modified botulinum neurotoxin A (BoNT / A) for use in the treatment of cervical dyskinesia wherein the modified BoNT / A is administered by intramuscular injection to affected neck muscles of a subject wherein the modified BoNT / A is administered in a unit dose of 750 pg to 17,000 pg of the modified BoNT / A, wherein at least a single unit dose is administered to the affected neck muscle wherein the total dose administered during treatment is at most 170,000 pg of the modified BoNT / A, and wherein the modified BoNT / A comprises a BoNT / A light chain and a translocation domain, and a BoNT / B receptor binding domain (HC domain). Related methods, uses, unit dosage forms, and kits are also provided.

The present disclosure provides antibodies that specifically bind to botulinum neurotoxin serotype BoNT / G. The antibodies can be used in methods to specifically bind and, in some embodiments, neutralize, botulinum neurotoxin and are therefore also useful in the treatment of pathologies associated with botulinum neurotoxin poisoning.

The invention is directed to treatment of limb spasticity using a modified botulinum neurotoxin A (BoNT / A) comprising a BoNT / A light-chain and translocation domain, and a BoNT / B receptor binding domain (HC domain). Also provided are unit dosage forms of said modified BoNT / A and corresponding kits.

The invention discloses a clostridium botulinum neurotoxin A receptor binding structural domain mutant with high affinity, and compared with a wild type clostridium botulinum neurotoxin A receptor binding structural domain, the clostridium botulinum neurotoxin A receptor binding structural domain mutant has any one of the following amino acid mutation sites: P1139S, L1154A, G1157L, R1140H, I1148N, L1154G, L1154Y, S1153G and Y1165W. The affinity of the botulinum neurotoxin A receptor binding domain mutant and a receptor SV2 is remarkably higher than that of a wild type, and the mutant and recombinant protein have wide application prospects in the fields of drug delivery, neurological disease treatment, biological detection and the like.

This document discloses clostridial neurotoxin (BoNT) or SNARE cleavage homolog variants, constructs, and methods of use thereof. The BoNT or SNARE cleavage homolog variants may include substitutions, deletions, or insertions of one or more amino acids or domains in the light chain.